Insilico Medicine Doses First Patient in GENESIS-IPF-3 Phase III Trial

Summary

CAMBRIDGE, Mass., Sep 10, 2026 — Insilico Medicine (“Insilico,” HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.